NAD+ and the 'felt it after one dose' claim: what research actually shows

A recent TikTok clip shows a user describing their first NAD+ experience, listing benefits such as energy production, brain clarity, cell repair, and mood support—and claiming they felt effects after just one dose. The caption frames NAD+ as a peptide, though it is technically a coenzyme. The video’s brevity leaves out important context about how NAD+ works, what forms are studied, and what a single session can realistically do.

What the clip is claiming

The creator implies that a single NAD+ administration produces immediate, noticeable improvements in energy, focus, and mood, while also supporting long-term cellular repair and anti-aging. The phrase “I felt it after ONE” is the core claim—suggesting rapid onset of subjective benefits. The video does not specify the form (e.g., NAD+ injection, nicotinamide riboside, or nicotinamide mononucleotide), the dose, or the route of administration.

What the research neighborhood actually covers

NAD+ (nicotinamide adenine dinucleotide) is a central coenzyme in cellular metabolism, particularly in redox reactions and as a substrate for sirtuins and PARPs. Research on NAD+ precursors—such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—has explored their role in mitochondrial function, DNA repair, and age-related decline. Human trials have shown that supplementation can raise NAD+ levels in blood and tissues, but studies on subjective outcomes like energy or mood are limited and mixed. Some trials report improvements in physical performance or fatigue, but these are typically over weeks, not after a single dose.

Limits, missing context, and what a 15-second clip cannot show

A short clip cannot convey the pharmacokinetics of NAD+ or its precursors. Intravenous NAD+ infusions are used in some clinics, but evidence for acute cognitive or mood benefits is anecdotal. The placebo effect is strong for subjective outcomes like “brain clarity” and “energy.” Additionally, the clip does not mention potential side effects, interactions, or the difference between acute and chronic effects. The claim of “cell repair” after one dose is biologically implausible—cellular repair pathways are ongoing and not triggered by a single administration.

How this maps to catalog compounds

NAD+ itself is not a peptide, but it is listed in the catalog as “NAD+” for research use. The clip’s focus on energy and anti-aging aligns with the coenzyme’s known role in cellular metabolism. However, the catalog also includes compounds that are sometimes discussed in similar contexts, such as MOTS-c (a mitochondrial-derived peptide) and SS-31 (Elamipretide), which target mitochondrial function. But the clip specifically mentions NAD+, so the review centers on that compound. No other catalog compound is directly relevant to the clip’s claims.

Research-use caveat

All catalog compounds are intended for research purposes only, not for human consumption or clinical use. The clip’s portrayal of NAD+ as a quick fix for energy and mood is not supported by rigorous clinical evidence for acute effects. Researchers studying NAD+ should focus on its biochemical pathways and long-term supplementation models, not on subjective self-reports from social media.

Open the full video fact-check page (transcript, takeaways, embedded clip).